Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential VAD and VTD Induction in MM
NCT00378755Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2006
- Countries
- 1
- Modality
- Small Molecules, Modified Peptides
- Drugs
- bortezomib
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM). Primary endpoint: Response Rate of Sequential VAD and VTD Induction. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Sequential VAD/VTD + ASCT + Maintenance
Sequential induction with VAD and VTD, followed by ASCT and Bortezomib maintenance.
03
Who it enrols
Newly diagnosed MM patients (Stage II-III) under 65 years old with adequate organ function and no severe neuropathy or cardiovascular disease.
04
Endpoints
Primary
Response Rate of Sequential VAD and VTD Induction
Secondary
Progression Free Survival
Duration of Response
Overall Survival
Toxicities
Beyond the preview
Go deeper on NCT00378755.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378755.